Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dmitry Balyasny Tripled His Keryx Biopharmaceuticals Position

Dmitry Balyasny is the founder of Balyasny Asset Management. He started his trading career at Schonfeld Securities in 1994. Balyasny’s Atlas Global fund returned 20+% average annual returns since its inception in 2002. The multistrategy hedge fund firm has around $2 Billion in AUM and specializes in long/short investing. Balyasny’s name was among the hedge funds being examined for illegal insider trading but no charges brought so far.

Keryx Biopharmaceuticals (NASDAQ:KERX)

Today, Balyasny disclosed a 5.92% stake in Keryx Biopharmaceuticals. At the end of December, Balyasny had 1.4 Million shares of KERX in its portfolio. He tripled his position in KERX through purchases made in late February and early March. The stock was trading below $4 around that time. Currently KERX’s latest price is $4.59. Balyasny gained more than 15% in less than two months from this transaction.

Dmitry Balyasny hired a healthcare team from Barclays in 2009. This is probably one of their stock picks. There were a couple of funds with very small holdings in KERX. Thomas Bailard’s Bailard Inc had 210 thousand shares and Brian Stark’s Stark Investments had 88 thousand shares at the end of December.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!